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Background: Chronic airway inflammatory disorders, such as asthma, are characterized by airway inflammation and
remodeling. Chronic inflammation and damage to the airway epithelium cause airway remodeling, which is associated
with improper epithelial repair, and is characterized by elevated expression of transforming growth factor-β (TGF-β).
Epithelial-mesenchymal transition (EMT) is an important mechanism during embryonic development and tissue
remodeling whereby epithelial cells gain the capacity to increase motility by down-regulation of epithelial
markers and up-regulation of mesenchymal markers. TGF-β is a central inducer of EMT, and TGF-β-induced EMT
is enhanced by pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α) and interleukin-1β. We
investigated whether the pro-inflammatory cytokine TWEAK (TNF-like weak inducer of apoptosis) enhanced
TGF-β1-induced EMT in the human bronchial epithelial cell line BEAS-2B.
Methods: Quantitative RT-PCR and western blotting were used to define alterations in epithelial and mesenchymal
marker expression in BEAS-2B cells. The cells were assessed for 48 h after stimulation with TGF-β1 alone or in combination
with TWEAK.
Results: TGF-β1 induced spindle-like morphology and loss of cell contact, and reduced the expression of epithelial marker
E-cadherin and increased the expression of mesenchymal markers N-cadherin and vimentin. Our data, for the first time,
show that TWEAK reduced the expression of E-cadherin, and that co-treatment with TGF-β1 and TWEAK enhanced the
TGF-β1-induced features of EMT. Moreover, hyaluronan synthase 2 expression was up-regulated by a combination with
TGF-β1 and TWEAK, but not TNF-α. We also demonstrated that the Smad, p38 MAPK, and NF-κB signaling pathways, and
the transcriptional repressor ZEB2 might mediate N-cadherin up-regulation by TGF-β1 in combination with TWEAK.
Conclusions: These findings suggest that the pro-inflammatory cytokine TWEAK and TGF-β1 have synergistic effects in
EMT and may contribute to chronic airway changes and remodeling.
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Although mechanisms of chronic airway inflammatory
disorders, including asthma, are not fully clarified, they
are all characterized by airway inflammation and remod-
eling [1,2]. Airway remodeling features basement mem-
brane thickening, excessive deposition of extracellular
matrix (ECM), mucus cell metaplasia, epithelial shedding,
angiogenesis, inflammatory cell infiltration, and smooth-
muscle cell and lung fibroblast proliferation [3]. Epithelial
repair consists of a complex cascade of events that starts
immediately after injury and leads to the organized re-
population of epithelial cells. Persistent epithelial damage
might be the result of incomplete repair where any com-
ponent of this cascade does not work properly. Therefore,
the combination of chronic epithelial injury and prolonged
epithelial repair leads to overproduction of pro-fibrotic
growth factors and the proliferation and differentiation of
fibroblasts into myofibroblasts. The exact mechanisms of
the origin of mesenchymal cell expansion are unknown,
although the expansion of the resident fibroblast popula-
tion and recruitment of fibrocytes from circulation have
both been implicated [4]. A recent report has suggested
that epithelial cells can contribute to the local fibroblast
pool during a process of molecular reprogramming called
epithelial-mesenchymal transition (EMT) [5]. EMT is also
an essential component of embryonic development, tissue
remodeling, and wound repair [6]. During this transition,
epithelial cells acquire the capacity to increase motility
through down-regulating epithelial markers, such as
E-cadherin, and increasing expression of mesenchymal
proteins, such as N-cadherin and vimentin [7,8]. EMT
can be induced by such growth factors as transforming
growth factor-β (TGF-β), which is secreted by various
cells including airway epithelial cells and infiltrating
immune cells [9-11]. It has been reported that house
dust mite and some pro-inflammatory cytokines, including
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-
1β), can enhance TGF-β-induced EMT in bronchial
epithelial cells [12-14]. In this regard, pro-inflammatory
cytokines can contribute to airway remodeling in chronic
inflammatory disorders.
TNF-like weak inducer of apoptosis (TWEAK) and its
receptor fibroblast growth factor-inducible 14 (Fn14)
have emerged as a ligand/receptor pair in the TNF
superfamily. Although the TWEAK/Fn14 interaction
contributes to pro-inflammatory effects and tissue remod-
eling [15,16] and high TWEAK expression was observed
in the skin of patients with atopic dermatitis as compared
with healthy subjects [17], the exact mechanisms that
underlie TWEAK-mediated airway remodeling have not
been elucidated. In the present study, we investigated
whether TWEAK induced EMT and enhanced TGF-β-
induced EMT. Our data, for the first time, show that
TWEAK down-regulates E-cadherin expression andaccelerates TGF-β1-induced EMT in bronchial epithe-
lial cells in an in vitro culture model. Moreover, hyalur-
onan synthase 2 expression was up-regulated by a
combination with TGF-β1 and TWEAK, but not TNF-α.
We also demonstrated that Smad-dependent and Smad-
independent signaling pathways, including p38 mitogen-
activated protein kinase (MAPK) and nuclear factor κB
(NF-κB), and the transcriptional repressor ZEB2 might
mediate N-cadherin up-regulation by TGF-β1 in combin-
ation with TWEAK. These findings suggest that TWEAK
has synergistic effects with TGF-β1-induced features of




Recombinant soluble human TGF-β1 and TWEAK were
from Peprotech (Rocky Hill, NJ, USA). Recombinant
soluble human TNF-α was obtained from eBioscience
(San Diego, CA, USA). Purified anti-α-tublin and anti-
human Vimentin (V9) monoclonal antibodies (mAbs)
SB431542 and AG1478 were from Sigma Chemicals
(St. Louis, MO, USA). Anti-human E-cadherin (HECD-1)
was from Takara (Tokyo, Japan). N-cadherin and anti-
EGFR mAbs were from BD Biosciences (San Jose, CA,
USA). Anti-phospho-EGFR (pY845) mAbs was from
abcam (Cambridge, UK). Anti-Smad2/3, anti-phospho-
Smad2 (Ser465/467), anti-extracellular signal-regulated
kinase (ERK), anti-phospho-ERK (Thr202/Tyr204), anti-
p38 MAPK, anti-phospho-p38 MAPK (Thr180/Tyr182),
anti-Akt, anti-phospho-NF-κB p65 (Ser536) polyclonal
antibodies, and anti-ZO-1, anti- Jun N-terminal kinase
(JNK), anti-phospho-JNK (Thr183/Tyr185), anti-phospho-
Akt (Ser473), and anti-NF-κB mAbs were obtained from
Cell Signaling Technology (Beverly, MA, USA). SB202190,
SP600125, LY294002, and BAY11-7082 were from Wako
Chemicals (Osaka, Japan). AZD6244 was from Selleckchem
(Houston, TX, USA). Bronchial epithelial growth medium
(BEGM) was purchased from Cambrex (East Rutherford,
NJ, USA).
Cell culture
The SV40-transformed normal human bronchial epithelial
cell line BEAS-2B was purchased from ATCC (Rockville,
MD, USA). Primary normal human bronchial epithelial
(NHBE) cells were purchased from Cambrex. Cells were
grown on collagen I-coated flasks or plates (Asahi Techno
Glass, Chiba, Japan). BEAS-2B cells and NHBE cells were
cultured in complete BEGM, which consists of bronchial
epithelial basal medium (BEBM) supplemented with
insulin (5 μg/ml), hydrocortisone (0.5 μg/ml), transferrin
(10 μg/ml), triiodothyronine (6.5 ng/ml), epinephrine
(0.5 μg/ml), human EGF (0.5 ng/ml), retinoic acid (0.1 ng/
ml), gentamycin (50 μg/ml), and bovine pituitary extract
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BEBM without growth factor and serum with or without
recombinant soluble human TGF-β1 (10 ng/ml), TNF-α
(10 ng/ml), or different concentrations of TWEAK (1-
100 ng/ml), which was as described in the Results.RNA Isolation and quantitative RT-PCR
Total cell RNA was isolated from bronchial epithelial
cells using the RNeasy plus mini kit (Qiagen, Valencia,
CA, USA) with DNase treatment, followed by cDNA
synthesis using the First-Strand cDNA Synthesis kit (GE
Healthcare, Little Chalfont, Buckinghamshire, UK) ac-
cording to the manufacturer’s instructions. Fast SYBR
Green Master Mix (Applied Biosystems, Foster City,
CA, USA) and an ABI 7500 Fast real-time PCR instru-
ment (Applied Biosystems, Warrington, UK) were used
for quantitative real-time reverse transcription-PCR
(qRT-PCR) with the gene specific primer pairs listed in
Table 1. For data analysis, the comparative threshold
cycle (CT) value for GAPDH was used to normalize
loading variations in the real-time PCRs. A ΔΔCT value
then was obtained by subtracting control ΔCT values
from the corresponding experimental ΔCT values. The
ΔΔCT values were converted to fold differences as com-
pared to the control by raising two to the ΔΔCT power.Preparation of cell lysates and western blotting
Whole cell lysates were prepared at the indicated time
points using RIPA buffer (50 mM Tris-HCl, pH 8.0,
150 mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1%
sodium dodecyl sulfate, 25 mM β-glycerophosphate, 1 mM
sodium orthovanadate, 1 mM sodium fluoride, 1 mM phe-
nylmethylsulfonyl fluoride, 1 μg/ml aprotinin, and 1 μg/ml
leupeptin). Protein concentration was determined by theTable 1 Primer sequences for real-time PCR













GAPDH GGTCTCCTCTGACTTCAACA GTGAGGGTCTCTCTCTTCCTBradford assay. Equal amounts of whole cell lysates
(10-20 μg) were separated by 8% or 10% SDS-PAGE
and blotted onto polyvinylidene difluoride membranes.
After blocking with 5% skim milk, blots were incubated
overnight with the indicated primary antibodies. Anti-
E-cadherin, anti-ZO-1, anti-EGFR, anti-phospho-EGFR,
anti-JNK, anti-phospho-JNK, anti-phospho-Akt, anti-NF-
κB mAbs, and anti-α-tublin mAbs, and anti-Smad2/3,
anti-phospho-Smad2, anti-ERK, anti-phospho-ERK, anti-
p38 MAPK, anti-phospho-p38 MAPK, anti-Akt, and anti-
phospho-NF-κB p65 polyclonal antibodies were used at 1/
1000 dilution. Anti-N-cadherin and Vimentin mAbs were
used at 1/500 and 1/4000 dilution, respectively. Mem-
branes were then incubated with appropriate horseradish
peroxidase-conjugated secondary antibodies (used at 1/
4000 dilution, GE Healthcare), followed by detection with
ECL Plus (GE Healthcare). All dilutions were in TBST
(Tris-buffered saline containing 0.1% Tween-20) supple-
mented with 5% bovine serum albumin. Densitometry of
western blot signals acquired with a Fuji LAS-4000 fluor-
escence imager (Fujifilm Corporation, Tokyo, Japan) with
a linearity of 4 orders of magnitude was performed using
NIH ImageJ image analysis software.
RNA interference assay
Lipofectamine RNAiMAX transfection agent and oligonu-
cleotides used in this study were purchased or custom-
synthesized by Life Technologies, Inc. (Grand Island, NY,
USA) and the sense and antisense sequences are listed in
Table 2. BEAS-2B cells were transfected with 20 nM small
interfering RNA (siRNA) duplexes using Lipofectamine
RNAiMAX according to the manufacturer’s instructions.
Briefly, siRNA duplexes and Lipofectamine RNAiMAX
were incubated in Opti-MEM I reduced serum medium
(Opti-MEM) (Life Technologies, Inc.) at room temperature
for 15 min. The cells were transfected with the siRNA/
Lipofectamine RNAiMAX complexes and seeded at a
density of 2.5 × 105 cells on 6-well plates. After incubation
for 24 h at 37°C, the transfected cells were treated with
the absence (control) or presence of TGF-β1 (10 ng/ml),
TNF-α (10 ng/ml), or TWEAK (100 ng/ml) for 48 h.
Knockdown efficacy was evaluated with quantitative real-
time RT-PCR at the designated time points.
Immunofluorescence staining for E-cadherin and
N-cadherin
Confluent monolayers grown on Nunc Lab-Tek chamber
slides (Thermo Scientific, Rockford, IL, USA) were fixed
with 4% paraformaldehyde for 10 min at room temperature
and stained with anti-E cadherin mAbs (used at 1/1000 di-
lution) or anti-N cadherin mAbs (used at 1/500 dilution),
followed by the secondary antibody (goat anti-mouse IgG
conjugated with Alexa594, used at 1/4000 dilution, Life
Technologies). Nuclei were stained with 4′, 6-diamidino-2-
Table 2 Oligonucleotide design
Target Sense primer(5′→ 3′) Antisense primer(5′ → 3′)
ZEB1 #1 AAACAGAGGACUCAGGCUUCUCAGC GCUGAGAAGCCUGAGUCCUCUGUUU
ZEB1 #2 UUAAGCAUGGAACACUGUUCUGGUC GACCAGAACAGUGUUCCAUGCUUAA
ZEB2 #1 UCAUACACUCCAAACAGCUUCUCUU AAGAGAAGCUGUUUGGAGUGUAUGA
ZEB2 #2 GAAAGAGAAGCUACGUACUUUAAUA UAUUAAAGUACGUAGCUUCUCUUUC
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captured using an epifluorescence microscope (Axioplan 2
imaging; Zeiss, Jena, Germany) and image acquisition was
performed with Axiovision 4.0 software (Zeiss).Monolayer wound-healing assay
We have established this method previously [18]. Briefly,
BEAS-2B and NHBE cells were grown in 6-well plate and
then placed upon confluence in the growth factor–free
BEBM. The circular wounds (~2.0 mm2) or linear wounds
were made in the confluent monolayer using a 20-μl pipette
tip (4 circular wounds or 1 × 1 linear wounds in each well).
In each experiment, one well was used as a negative control
with no treatment. The wounds were imaged 0 and
48 hours after wound creation using a Nikon Eclipse TE200
inverted microscope equipped with a Nikon Coolpix E995.
Corresponding wound areas were determined using Image-
Pro Plus and the remaining wound areas were calculated as
a percentage of area at time 0.Flow cytometric analysis
BEAS-2B cells (0.5–1.0 × 106) were incubated with
Phycoerythrin-conjugated anti-Fn14 mAbs (eBioscience,
San Diego, CA, USA). After washing with PBS twice, the
stained cells (live gated on the basis of forward and side
scatter profiles and propidium iodide exclusion) were
analyzed with a FACSCalibur system (BD Biosciences,
Mountain View, CA, USA), and data were processed by
using the CellQuest program (BD Biosciences).Proliferation assay
An equivalent number of cells (5.0 × 103/well) was flat-
bottomed 96-well microtiter plate and allowed to adhere
for 24 h at 37°C. After washing with PBS twice, cells were
incubated with fresh BEBM without growth factor and
serum with or without recombinant soluble human TGF-
β1 (10 ng/ml), TNF-α (10 ng/ml), or different concentra-
tions of TWEAK (1-100 ng/ml) for 48 h at 37°C. After
treatment, 10 μl Cell counting Kit 8 solution (Dojindo La-
boratories, Kumamoto, Japan) was added to each well, and
the 96-well plates were continuously incubate at 37°C for 2
h. Absorbance was read at 450 nm on a Microplate reader
with Microplate manager (Bio-Rad Laboratories, Hercules,
CA, USA).Statistical analysis
Comparisons between multiple groups were made by
one-way ANOVA with Tukey’s multiple comparisons test
using the program GraphPad Prism version 6 (GraphPad
Software, San Diego, CA, USA). Differences were consid-
ered to be statistically significant when p values were 0.05
or less.
Results
TWEAK regulates E-cadherin expression and enhances
TGF-β1-induced EMT in bronchial epithelial cells
A previous report demonstrated that BEAS-2B cells ex-
press TWEAK receptor Fn14 [19]. We also confirmed
by flow cytometric analysis that this receptor existed on
BEAS-2B cells (Additional file 1: Figure S1). We first in-
vestigated whether exogenous TWEAK could induce
EMT and enhance TGF-β1-induced EMT similarly to
TNF-α in BEAS-2B cells. Confluent monolayers of
BEAS-2B cells were treated with or without TGF-β1
(10 ng/ml), TNF-α (10 ng/ml), TWEAK (100 ng/ml), or
TGF-β1 in combination with TNF-α or TWEAK. We de-
cided to use a dose of 100 ng/ml TWEAK as a stimulus
because TWEAK in a similar concentration was used in
most previous reports [16,19-22]. Phase contrast micros-
copy showed that cells treated with TNF-α or TWEAK in
combination with TGF-β1, compared with control and
TGF-β1 alone, exhibited spindle-like morphology and loss
of cell contact (Figure 1). Immunofluorescent staining of
BEAS-2B cells, which usually express high levels of E-
cadherin, revealed dramatically reduced expression of this
adherens junction protein after 48 h of treatment with
TGF-β1 alone, TNF-α, or TWEAK (Figure 1). Moreover,
TGF-β1 in combination with TNF-α or TWEAK more
strongly down-regulated the expression of E-cadherin
by immunohistochemistry as compared with treatment
with TGF-β1 alone (Figure 1). Furthermore, TGF-β1 in-
duced N-cadherin expression and TGF-β1 in combin-
ation with TNF-α or TWEAK more strongly induced
N-cadherin expression in immunofluorescent staining
of BEAS-2B cells (Figure 1). Additionally, total RNAs
and whole cell lysates were isolated from the cells at
48 h after treatment with or without TGF-β1 (2 or
10 ng/ml), TNF-α (10 ng/ml), different concentrations
of TWEAK (1-100 ng/ml), or TGF-β1 in combination
with TNF-α or TWEAK (1-100 ng/ml). The levels of E-
cadherin, ZO-1 and N-cadherin mRNA and protein
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blotting, respectively. Compared with controls, BEAS-2B
cells treated with TGF-β1, TNF-α, or a combination of
TGF-β1 and TNF-α exhibited down-regulation of mRNA
and protein expression of E-cadherin as an epithelial
marker (Figures 1, 2A and 2D), and up-regulation of N-
cadherin expression as a mesenchymal marker (Figures 1,
2C and 2F). TWEAK alone and in combination with TGF-
β1 also down-regulated the expression of E-cadherin
(Figures 1, 2A and 2D, and Additional file 2: Figure S2A).
Moreover, TWEAK in combination with TGF-β1 alsoFigure 1 Changes of morphology and E-cadherin and N-cadherin pro
Confluent monolayers of BEAS-2B cells were cultured for 48 h in the absen
TWEAK (100 ng/ml), or TGF-β1 in combination with TNF-α or TWEAK. E-cad
staining. The nuclei were stained with DAPI for DNA (blue). Scale bar 40 μmdown-regulated the expression of ZO-1 as an epithelial
marker (Figure 2B and 2E) and up-regulated the expression
of N-cadherin (Figure 2C and 2F and Additional file 2:
Figure S2B) in a dose-dependent manner. Furthermore,
the protein levels of another mesenchymal marker,
vimentin, were enhanced by TGF-β1 alone, TWEAK
alone, and by combinations of TGF-β1 and TNF-α or
TWEAK (Figure 2G). Additionally, expression of the
major ECM-related genes was examined. Additional file
3: Figure S3 showed that a combination of TGF-β1 and
TNF-α, but not TWEAK, enhanced TGF-β1-inducedtein levels in BEAS-2B cells upon TGF-β1 and TWEAK treatment.
ce (control) or presence of TGF-β1 (10 ng/ml), TNF-α (10 ng/ml),
herin and N-cadherin (red) was assessed by immunofluorescent
.
Figure 2 (See legend on next page.)
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Figure 2 Cooperative induction of EMT in BEAS-2B cells by TGF-β1 and TWEAK. Confluent monolayers of BEAS-2B cells were cultured for
48 h in the absence (control) or presence of TGF-β1 (10 ng/ml), TNF-α (10 ng/ml), different concentrations of TWEAK (1-100 ng/ml), or TGF-β1 in
combination with TNF-α or TWEAK (1-100 ng/ml) as indicated. The levels of E-cadherin (A), ZO-1 (B), N-cadherin (C), and HAS2 (H) mRNA were
analyzed by qRT-PCR. Expression levels were normalized to the housekeeping gene GAPDH and calculated as fold induction in comparison to the
control. Whole cell lysates were immunoblotted for E-cadherin (D, upper), ZO-1 (E, upper), N-cadherin (F, upper), or vimentin (G, upper). All
membranes were re-probed with anti-α-tublin antibody to confirm equal loading. The density of each band was normalized with α-tubulin
and quantified by densitometry using NIH ImageJ software (D-G, lower). The capability of cell migration was assessed using a wound-healing assay (I).
Data represent the means ± SD of three independent experiments. *p < 0.05 compared with the untreated culture. †p < 0.05 compared with
TGF-β1 alone.
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sion of another ECM constituent, hyaluronan synthase 2
(HAS2), which is one of the hyaluronan synthase enzyme,
increased by TWEAK and the combinations of TGF-β1
and TWEAK, but not TNF-α (Figure 2H).
We next examined cell migration, which was assessed
using a wound-healing assay, as important hallmarks of
EMT. Compared with controls, BEAS-2B cells treated
with a combination of TGF-β1 and TNF-α or TWEAK
exhibited significant migration in wound-healing assay
(Figure 2I and Additional file 4: Figure S4). However, the
treatment with TGF-β1, TNF-α, TWEAK, or TGF-β1 in
combination with TNF-α or TWEAK had no effect on
proliferation of BEAS-2B cells (Additional file 5: Figure S5).
Further we investigated whether TWEAK could down-
regulate E-cadherin expression and enhance TGF-β1-
induced EMT in primary cultures of NHBE cells. In NHBE
cells, TWEAK down-regulated E-cadherin expression and
enhanced TGF-β1-induced E-cadherin down-regulation
and N-cadherin up-regulation and exhibited significant
migration in wound-healing assay (Figure 3). These re-
sults indicate that not only TNF-α, but also TWEAK
can down-regulate E-cadherin expression and enhance
TGF-β1-induced EMT in bronchial epithelial cells.
Smad-dependent and Smad-independent signaling
pathways are required for N-cadherin up-regulation, but not
E-cadherin down-regulation, caused by a combination of
TGF-β1 and TWEAK
Next, we investigated whether Smad-dependent and
Smad-independent signaling pathways are required for the
TWEAK-enhanced EMT that was induced by TGF-β1.
Confluent monolayers of BEAS-2B cells were cultured for
0.5 h or 1 h with or without TGF-β1 (10 ng/ml), TWEAK
(100 ng/ml), or TGF-β1 in combination with TWEAK.
Although TGF-β1 increased Smad2 phosphorylation,
TWEAK had no additional effect on it (Figure 4). Add-
itionally, Smad2 phosphorylation and N-cadherin up-
regulation induced by TGF-β1 or a combination of
TGF-β1 and TNF-α or TWEAK was completely inhib-
ited by SB431542 (10 μM), an inhibitor of the TGF-β
receptor type 1 (TβRI) kinase, which is known to be an
activator of the Smad pathway (Figures 4B and 5B). In
contrast, SB431542 was not found to attenuate TNF-αor TWEAK-mediated E-cadherin down-regulation, al-
though down-regulation of E-cadherin induced by TGF-
β1 was attenuated by SB431542 (Figure 5A). These results
suggest that Smad-dependent pathways are required for
N-cadherin up-regulation by TGF-β1 or a combination of
TGF-β1 and TWEAK, but are not required for TWEAK-
mediated E-cadherin down-regulation. Conversely, add-
itional Smad-independent pathways may be required for
TWEAK-enhanced TGF-β1-induced EMT.
TGF-β1 also activates Smad-independent pathways
such as ERK, p38 MAPK, JNK, phosphatidylinositol 3-
kinase (PI3K)/Akt, and NF-κB [23]. To explore the involve-
ment of Smad-independent pathways in TWEAK-induced
E-cadherin down-regulation and TWEAK-enhanced
TGF-β1-induced EMT, we examined whether a combin-
ation with TGF-β1 and TWEAK could activate Smad-
independent pathways. TGF-β1 in combination with
TNF-α or TWEAK led to activation of the Smad-
independent pathways via phosphorylation of ERK, p38
MAPK, JNK, PI3K/Akt, NF-κB, and epidermal growth
factor receptor (EGFR) (Additional file 6: Figure S6).
TWEAK alone also induced the phosphorylation of
ERK, JNK, PI3K/Akt, NF-κB, and EGFR. Especially,
TWEAK induced the phosphorylation of JNK to higher
levels than those induced by a combination with TGF-
β1 and TNF-α. Furthermore, these phosphorylations
were inhibited by each inhibitor, including AZD6244
(RAF/MEK/ERK pathway inhibitor), SB202190 (p38
MAPK inhibitor), SP600125 (JNK inhibitor), LY294002
(PI3K inhibitor), BAY11-7082 (NF-κB inhibitor), or
AG1478 (EGFR inhibitor).
We next investigated whether inhibitors for Smad-
independent pathways had any effect on TWEAK-
mediated EMT. Confluent monolayers of BEAS-2B cells
were cultured for 48 h with or without TGF-β1, TNF-α,
TWEAK, or TGF-β1 in combination with TNF-α or
TWEAK, and were treated with or without SB431542,
AG1478, AZD6244, SB202190, SP600125, LY294002, or
BAY11-7082. As shown in Figure 5A, these inhibitors
without SB431542 had no apparent effect on the E-
cadherin down-regulation that was induced by TGF-β1,
TNF-α, TWEAK, and the combinations with TGF-β1. In
contrast, N-cadherin up-regulation induced by TGF-β1
or a combination of TGF-β1 and TNF-α or TWEAK
Figure 3 Cooperative induction of EMT in NHBE cells by TGF-β1
and TWEAK. Confluent monolayers of NHBE cells were cultured for
48 h in the absence (control) or presence of TGF-β1, TNF-α, TWEAK,
or TGF-β1 in combination with TNF-α or TWEAK, as indicated. The
levels of E-cadherin (A) and N-cadherin (B) mRNA were analyzed by
qRT-PCR. Expression levels were normalized to the housekeeping
gene GAPDH and calculated as fold induction in comparison to the
control. Whole cell lysates were immunoblotted for E-cadherin (C, upper)
and N-cadherin (D, upper). All membranes were re-probed with
anti-α-tublin antibody to confirm equal loading. The density of each
band was normalized with α-tubulin and quantified by densitometry
using NIH ImageJ software (C and D, lower). The capability of cell
migration was assessed using a wound-healing assay (E). Data represent
the means ± SD of three independent experiments. *p< 0.05 compared
with the untreated culture. †p< 0.05 compared with TGF-β1 alone.
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BAY11-7082, although AG1478, AZD6244, SP600125,
and LY294002 had no effect on N-cadherin up-
regulation (Figure 5B). Moreover, we examined whether
SB202190 and BAY11-7082 could inhibit the protein
levels of N-cadherin which were induced by the combin-
ation of TGF-β1 and TWEAK. Figure 6 and Additional
file 7: Figure S7 showed that TGF-β1 in combination
with TNF-α- or TWEAK-induced N-cadherin expressions
was partially inhibited by SB202190 and BAY11-7082 in
BEAS-2B and NHBE cells, but not SP600125 in BEAS-2B
cells. These results suggest that Smad-dependent pathways
and p38 MAPK and NF-κB, which are Smad-independent
pathways, play an important role in N-cadherin up-
regulation by a combination of TGF-β1 and TWEAK in
bronchial epithelial cells. However, p38 MAPK and NF-κB
were not required for TWEAK-induced and TWEAK-
enhanced E-cadherin down-regulation.
TWEAK induces mRNA expression of transcriptional
repressors ZEB1 and ZEB2 in BEAS-2B cells
Recently, it was reported that EMT is controlled by a
group of transcriptional repressors [24,25]. The zinc-
finger-containing proteins Snail, Slug, ZEB1, ZEB2 (also
denoted SIP1), and the helix-loop-helix transcription
factors Twist are important transcriptional repressors
that bind to the E-boxes in the promoter of the E-
cadherin gene and actively repress its expression [24,25].
To examine whether transcriptional repressors mediated
the TWEAK-enhanced EMT that was induced by TGF-
β1 in BEAS-2B cells, total RNA was extracted from
stimulated monolayers of BEAS-2B cells with or without
TGF-β1, TWEAK, or TGF-β1 in combination with TNF-α
or TWEAK. TGF-β1 significantly increased the expression
of Snail and Slug mRNA (Figure 7A and B). TWEAK
treatment with TGF-β1 at 8 h significantly repressed the
TGF-β1-induced Snail mRNA expressions (Figure 7A). Al-
though TWEAK significantly increased the expression of
Twist mRNA, TWEAK in combination with TGF-β1
Figure 4 TWEAK had no additional effect on TGF-β1-induced Smad2 phosphorylation. Confluent monolayers of BEAS-2B cells were cultured
for the indicated time points in the absence (conrol or DMSO as vehicle) or presence of SB43125 (10 μM) and treated with TGF-β1 (10 ng/ml),
TNF-α (10 ng/ml), TWEAK (100 ng/ml), or TGF-β1 in combination with TNF-α or TWEAK, as indicated. Whole cell lysates were prepared at the
indicated time points (A) and 1 h (B) after treatment. Phosphorylation of Smad2 was examined by western blotting. Densitometry of pSmad2
signals was normalized against total Smad2 signals. Data represent the means ± SD of three independent experiments. *p < 0.05 compared
with the untreated culture. †p < 0.05 compared with TGF-β1 alone. §p < 0.05 compared with vehicle.
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TGF-β1, TWEAK, and a combination of TGF-β1 and
TNF-α or TWEAK significantly increased mRNA expres-
sion of ZEB1 and ZEB2 (Figure 7D and E), suggesting that
ZEB1/2 may be required for TWEAK stimulation in bron-
chial epithelial cells.
Knockdown of ZEB2, but not of ZEB1, reduces TWEAK-
enhanced N-cadherin mRNA expression in BEAS-2B cells
We next examined whether ZEB1/2 were required for
TWEAK-enhanced TGF-β1-induced EMT. BEAS-2B cells
were transfected with control siRNA, ZEB1 siRNA, or
ZEB2 siRNA. After incubation for 24 h, the transfected cells
were treated with or without TGF-β1, TNF-α, TWEAK, or
a combination of TGF-β1 and TNF-α or TWEAK for 48 h.
We showed that knockdown efficiency was evaluated with
quantitative real-time RT-PCR for 72 h hours (Additional
file 8: Figure S8). In cells treated with ZEB2 siRNA, but not
ZEB1 siRNA, up-regulation of N-cadherin mRNA expres-
sion was reduced (Figure 8). In contrast, ZEB1 and ZEB2
knockdown had no effect on E-cadherin expression (data
not shown). These RNA interference assays suggested that
the transcriptional repressor ZEB2 may be required for N-
cadherin up-regulation in bronchial epithelial cells.
p38 MAPK and NF-κB inhibitors inhibit TWEAK-induced
mRNA expression of ZEB2 in BEAS-2B cells
We finally investigated whether Smad-independent path-
ways, including p38 MAPK and NF-κB, were required
for TWEAK-mediated mRNA expression of ZEB2. Con-
fluent monolayers of BEAS-2B cells were cultured for48 h with or without TGF-β1, TNF-α, TWEAK, or TGF-
β1 in combination with TNF-α or TWEAK, and were
treated with or without SB202190 or BAY11-7082. As
shown in Figure 9, ZEB2 mRNA up-regulation induced by
TWEAK was completely inhibited by BAY11-7082 and
partially attenuated by SB202190. However, ZEB2 mRNA
up-regulation induced by the combination of TGF-β1 and
TWEAK was completely inhibited by BAY11-7082 but
not by SB202190. These data suggest that at least the p38
MAPK and NF-κB pathways are required for TWEAK-
induced mRNA expression of the transcriptional repressor
ZEB2 in bronchial epithelial cells.
Discussion
To our knowledge, this is the first study to show that
TWEAK reduced the expression of E-cadherin, and that
co-treatment with TGF-β1 and TWEAK enhanced the
TGF-β1-induced features of EMT in bronchial epithelial
BEAS-2B and NHBE cells. The gain of N-cadherin mes-
enchymal markers by the combination of TGF-β1 and
TWEAK was completely abrogated by an inhibitor of
the TβRI kinase signaling pathway, suggesting that
TWEAK-mediated N-cadherin up-regulation requires the
presence of TGF-β1. Furthermore, we also found that
TWEAK accelerates TGF-β1-induced N-cadherin up-
regulation via Smad-dependent and Smad-independent
pathways, including p38 MAPK and NF-κB, in BEAS-2B
cells. Additionally, previous reports have indicated that
EMT is also regulated by a group of transcriptional repres-
sors, including Snail, Slug, Twist, ZEB1, ZEB2, and the
NF-κB transcription factor family [26]. Our experiments
Figure 5 The combination of TGF-β1 and TWEAK-induced N-cadherin up-regulation required Smad, p38 MAPK, and NF-κB signaling
pathways. Confluent monolayers of BEAS-2B cells were cultured for 48 h in the absence (DMSO as vehicle) or presence of SB43125 (10 μM),
AG1478 (1 μM), AZD6244 (5 μM), SB202190 (5 μM), SP600125 (5 μM), LY294002 (5 μM), or BAY11-7082 (2.5 μM) and treated with TGF-β1 (10 ng/ml), TNF-α
(10 ng/ml), TWEAK (100 ng/ml), or TGF-β1 in combination with TNF-α or TWEAK, as indicated. The levels of E-cadherin (A) and N-cadherin (B) mRNAs were
analyzed by qRT-PCR. Expression levels were normalized to the housekeeping gene GAPDH and calculated as fold induction in comparison to vehicle. Data
represent the means ± SD of three independent experiments. *p< 0.05 compared with vehicle.
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Figure 6 The combination of TGF-β1 and TWEAK-induced N-cadherin up-regulation required p38 MAPK and NF-κB signaling pathways.
Confluent monolayers of BEAS-2B cells (A and B) and NHBE cells (C and D) were cultured for 48 h in the absence (DMSO as vehicle) or presence
of SB202190 (5 μM) (A and C) and BAY11-7082 (2.5 μM) (B and D) and treated with TGF-β1, TWEAK, or TGF-β1 in combination with TNF-α or
TWEAK, as indicated. Whole cell lysates were immunoblotted for N-cadherin (upper). The membranes for N-cadherin were re-probed with anti-α-
tublin antibody to confirm equal loading. The density of N-cadherin was normalized with α-tubulin and quantified by densitometry (lower). Data
represent the means ± SD of three independent experiments. *p < 0.05 compared with vehicle.
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regulator of N-cadherin up-regulation. Moreover, we also
revealed that TWEAK-induced ZEB2 mRNA expression
requires p38 MAPK and NF-κB pathways. One limitation
of our study was that we used monolayers of BEAS-2B
and NHBE cells which show characteristics of non-
differentiated basal human bronchial epithelial cells.
We recently demonstrated that EGFR transactivation
is required for TGF-β enhanced epithelial wound repair
[9]. In this report, although TGF-β1 and TWEAK induce
the phosphorylation of EGFR, an EGFR inhibitor had no
effect on EMT, suggesting that EGFR transactivation is not
required for the TGF-β1-induced and TWEAK-mediated
features of EMT. We also revealed that TWEAK alone
and in combination with TGF-β1 induced E-cadherin
down-regulation, that TWEAK had no effect on Smad2
phosphorylation, and that various inhibitors of Smad-dependent and Smad-independent signaling pathways
could not suppress TWEAK-mediated E-cadherin down-
regulation. Further studies are needed to investigate
whether another signaling pathway or the combinations of
these pathways are required for TWEAK-mediated E-
cadherin down-regulation in bronchial epithelial cells, be-
cause we were not able to elucidate that mechanism.
Asthma may be accompanied by a decline in lung
function despite anti-inflammatory treatment. This clinical
feature has been associated with structural changes in the
bronchial tissue termed airway remodeling [27,28]. The
pathogenesis of airway remodeling has been previously at-
tributed to a cycle of persistent airway epithelial damage,
improper repair, and EMT, which is a complex reprogram-
ming process of epithelial cells. Many lines of evidence
imply that EMT is controlled by TGF-β1 as a major patho-
genic factor. We recently reported that mechanical injury
Figure 7 TWEAK induces mRNA expression of transcriptional
repressors ZEB1 and ZEB2. Confluent monolayers of BEAS-2B cells
were cultured for the indicated time points in the absence (control)
or presence of TGF-β1 (10 ng/ml), TNF-α (10 ng/ml), TWEAK
(100 ng/ml), or TGF-β1 in combination with TNF-α or TWEAK. The
levels of Snail (A), Slug (B), TWIST (C), ZEB1 (D), and ZEB2 (E) mRNAs
were analyzed by qRT-PCR. Expression levels were normalized to the
housekeeping gene GAPDH and calculated as fold induction in
comparison to 0 h. Data represent the means ± SD of three independent
experiments. *p< 0.05 compared with 0 h. †p< 0.05 compared with
TGF-β1 alone.
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TGF-β1 and TGF-β2, which enhances epithelial wound re-
pair [9]. Puddicombe et al. have shown that the disruption
of epithelial repair leads to enhanced release of TGF-β2 by
bronchial epithelial cells [29]. Moreover, we also reported
that bronchial epithelial cells produce increased amounts of
IL-13 during improper wound repair [18]. Taken together,
these reports indicate that improper bronchial epithelial re-
pair causes a persistent repair phenotype with overproduc-
tion of inflammatory mediators and cytokines, including
TGF-β and IL-13 which are central mediators of asthma. It
is also recognized from recent studies that a number of key
pro-inflammatory cytokines, including IL-1β and TNF-α,
are able to enhance TGF-β-induced EMT in epithelial cells
[12,13,30]. Here, we provide the first evidence, to our
knowledge, that the TNF superfamily protein TWEAK ac-
celerates the TGF-β-induced features of EMT in bronchial
epithelial cells in an in vitro culture model. Orchestrated
cellular processes with TGF-β and TWEAK in airway epi-
thelial cells causes enhanced EMT, which may contribute
to chronic airway changes and remodeling.
Our data of ECM production have suggested produ-
cing different ECM profiles of bronchial epithelial cells
according to the stimulation of TGF-β, TNF-α, or
TWEAK. Although the expressions of Tenascin-C and
fibronectin were up-regulated by a combination with
TGF-β1 and TNF-α, but not TWEAK, HAS2 expression
was up-regulated by a combination with TGF-β1 and
TWEAK, but not TNF-α. It was reported that TNF-α
promoted CD44 expression and leading to the inter-
action of CD44 and hyaluronan which was synthesized
by HAS [30]. Moreover, TGF-β1-induced EMT depends
on HAS2 in normal mouse mammary epithelial cells
[31]. Together, these results and previous reports suggest
that EMT requires not only TGF-β1 and TNF-α, but
also TWEAK which induced HAS2 expression.
TWEAK is a multifunctional cytokine that may promote
cell death, cell proliferation, inflammation, and angiogenesis
[32,33]. Also, TWEAK and its receptor, Fn14, are up-
regulated in cancer, and TWEAK-induced signaling pro-
motes multiple processes known to contribute to tumor
growth [15,34,35]. However, it is not clear whether tumor
metastasis requires TWEAK. Our findings show that the
Figure 8 ZEB2 knockdown reduces TWEAK-enhanced N-cadherin mRNA expression. Total RNA was extracted from BEAS-2B cells treated
with or without TGF-β1 (10 ng/ml), TNF-α (10 ng/ml), TWEAK (100 ng/ml), or TGF-β1 in combination with TNF-α or TWEAK for 48 h at 72 h after
transfection with control siRNA, ZEB1 siRNA (A), or ZEB2 siRNA (B). The levels of N-cadherin mRNA were analyzed by qRT-PCR. Expression levels
were normalized to the housekeeping gene GAPDH and calculated as fold induction in comparison to control. Data represent the means ± SD of
three independent experiments. *p < 0.05 compared with scrambled control siRNA.
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tor of the TGF-β1-induced EMT that is an important com-
ponent of tumor metastasis. Furthermore, TWEAK has
already been evaluated as a target molecule in antitumor
therapy using RG7212, an antagonistic anti-TWEAK anti-
body [35]. Preliminary results from a phase I study of
RG7212 have reported decreased tumor cell proliferation
and pathway activity plus immune cell changes in patients
with advanced malignant melanoma, non-small cell lung
cancer, mesothelioma, kidney cancer, and biliary tract can-
cer without any serious adverse side-effects [36]. Further
studies are needed to assess the potential of RG7212Figure 9 TWEAK-induced ZEB2 mRNA expression was inhibited by inh
cells were cultured for 48 h in the absence (DMSO as vehicle) or presence
TGF-β1 (10 ng/ml), TNF-α (10 ng/ml), TWEAK (100 ng/ml), or TGF-β1 in com
were analyzed by qRT-PCR. Expression levels were normalized to the house
to vehicle. Data represent the means ± SD of three independent experimentherapy for airway remodeling of chronic airway inflamma-
tory disorders such as asthma and interstitial pneumonia.
Conclusions
We have revealed a novel mechanism of EMT in bron-
chial epithelial cells. TWEAK induced down-regulation of
E-cadherin and enhanced EMT-like phenotypic changes
by TGF-β1 in bronchial epithelial cells. Furthermore,
TWEAK-mediated N-cadherin up-regulation might re-
quire Smad-dependent and Smad-independent pathways,
including p38 MAPK and NF-κB, and the transcriptional
repressor ZEB2. These findings suggest that the pro-ibitors of p38 MAPK and NF-κB. Confluent monolayers of BEAS-2B
of SB202190 (5 μM) (A) or BAY11-7082 (2.5 μM) (B) and treated with
bination with TNF-α or TWEAK, as indicated. The levels of ZEB2 mRNA
keeping gene GAPDH and calculated as fold induction in comparison
ts. *p < 0.05 compared with vehicle alone.
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β1 in EMT and may contribute to chronic airway changes
and remodeling.Additional files
Additional file 1: Figure S1. Cell surface expression of Fn14 on BEAS-2B
cells. After 48 hours of serum starvation, confluent monolayers of BEAS-2B cells
were collected and analyzed by flow cytometry. Black and gray lines indicate
marker expression and the isotype control staining, respectively.
Additional file 2: Figure S2. TGF-β1 in combination with TWEAK
induced E-cadherin down-regulation and N-cadherin up-regulation in a
dose-dependent manner. Confluent monolayers of BEAS-2B cells were
cultured for 48 h in the absence or presence of TGF-β1 (2 or 10 ng/ml)
and TWEAK (100 ng/ml), as indicated. The levels of E-cadherin (A) and
N-cadherin (B) mRNA were analyzed by qRT-PCR. Expression levels were
normalized to the housekeeping gene GAPDH and calculated as fold
induction in comparison to the control. Data represent the means ± SD
of three independent experiments. *p < 0.05 compared with the untreated
culture. †p < 0.05 compared with 2 ng/ml of TGF-β1.
Additional file 3: Figure S3. A combination of TGF-β1 and TNF-α, but
not TWEAK, enhanced TGF-β1-induced mRNA expression of Tenascin-C
and fibronectin as an extracellular matrix protein. Confluent monolayers
of BEAS-2B were cultured for 48 h in the absence or presence of TGF-β1
(10 ng/ml), TNF-α (10 ng/ml), TWEAK (100 ng/ml), or TGF-β1 in combination
with TNF-α or TWEAK, as indicated. The levels of Tenascin-C (A) and fibronectin
(B) mRNA were analyzed by qRT-PCR. Expression levels were normalized to
the housekeeping gene GAPDH and calculated as fold induction in
comparison to the control. Data represent the means ± SD of three
independent experiments. *p < 0.05 compared with the untreated
culture. †p < 0.05 compared with TGF-β1 alone.
Additional file 4: Figure S4. Cell migration analysis by wound-healing
assay. Confluent monolayers of BEAS-2B cells were subjected to linear
injuries using a 20-μl pipette tip and then cultured in the absence (control)
or presence of TGF-β1 (10 ng/ml), TNF-α (10 ng/ml), TWEAK (100 ng/ml), or
TGF-β1 in combination with TNF-α or TWEAK as indicated. Photographs
were taken 0 and 48 hours after wound creation. Scale bar 300 μm.
Additional file 5: Figure S5. The treatment with TGF-β1, TNF-α, TWEAK,
or TGF-β1 in combination with TNF-α or TWEAK had no effect on proliferation
assay in BEAS-2B cells. Cells were incubated with or without TGF-β1 (10 ng/
ml), TNF-α (10 ng/ml), or different concentrations of TWEAK (1-100 ng/ml) for
48 h. Cell proliferation was monitored using Cell counting Kit 8. Data represent
the means ± SD of three independent experiments.
Additional file 6: Figure S6. The combination with TGF-β1 and TWEAK
activate Smad-independent signaling pathways. Confluent monolayers of
BEAS-2B cells were cultured in the absence (DMSO as vehicle) or presence
of AZD6244 (5 μM), SB202190 (5 μM), SP600125 (5 μM), LY294002 (5 μM), or
BAY11-7082 (2.5 μM), AG1478 (1 μM) and treated with TGF-β1 (10 ng/ml),
TNF-α (10 ng/ml), TWEAK (100 ng/ml), or TGF-β1 in combination with TNF-α
or TWEAK, at different times of incubation: ERK, p38 MAPK, and p65 NF-κB at
30 min; JNK, PI3K, and EGFR at 1 h. Whole cell lysates were immunoblotted
for phosphorylation of ERK (A, upper), p38 MAPK (B, upper), JNK (C, upper),
PI3K (D, upper), p65 NF-κB (E, upper), and EGFR (F, upper). Densitometry of
these signals was normalized against total ERK, p38 MAPK, JNK, PI3K, NF-κB,
and EGFR signals, respectively (lower). Data represent the means ± SD
of two independent experiments. *p < 0.05 compared with vehicle
control. †p < 0.05 compared with vehicle.
Additional file 7: Figure S7. SP600125, JNK inhibitor, had no apparent
effect on the N-cadherin up-regulation by a combination of TGF-β1
and TWEAK. Confluent monolayers of BEAS-2B cells were cultured for
48 h in the absence (DMSO as vehicle) or presence of SP600125 (5
μM) and treated with TGF-β1, TWEAK, or TGF-β1 in combination with
TNF-α or TWEAK, as indicated. Whole cell lysates were immunoblotted
for N-cadherin (upper). The membranes for N-cadherin were re-probed with
anti-α-tublin antibody to confirm equal loading. The density of N-cadherin
was normalized with α-tubulin and quantified by densitometry (lower). Datarepresent the means ± SD of two independent experiments. *p < 0.05
compared with vehicle.
Additional file 8: Figure S8 Knockdown efficiency of ZEB1 and ZEB2
mRNA expression. Total RNA was extracted from BEAS-2B cells treated
with or without TGF-β1 (10 ng/ml), TNF-α (10 ng/ml), TWEAK (100 ng/ml),
or TGF-β1 in combination with TNF-α or TWEAK for 48 h at 72 h after
transfection with control siRNA, ZEB1 siRNA (A), or ZEB2 siRNA (B). The
levels of ZEB1 and ZEB2 mRNA were analyzed by qRT-PCR. Expression
levels were normalized to the housekeeping gene GAPDH and calculated
as fold induction in comparison to the control. Data represent the means ±
SD of three independent experiments. *p < 0.05 compared with scrambled
control siRNA.
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